PMA device
Promote/+/RF/Q
Abbott Medical · Defibrillator, Automatic Implantable Cardioverter, With Cardiac Resynchronization (Crt-D) (NIK, Class III) · First FDA decision May 12, 2016, newest Jul 21, 2026Heart failureVentricular arrhythmia and sudden cardiac arrest
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
8
PMA pathway
Device trials
4
Naming "Promote + RF"
MAUDE reports
208
Brand "Promote + RF", since 2015
PubMed studies
0
Mentioning "Promote + RF"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Promote/+/RF/Q
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 6 of 8 decisions filed under this name.
- Promote/+/RF/Q, Promote Accel, Promote Quadra, Unify, Unify Assura, Unify Quadra, Quadra Assura, Epic+/HF/HF+/II HF/II+PMA supplement
P030054-S440 · Decided Jul 21, 2026 · 203 days after receipt · Normal 180 Day Track
Device type: Defibrillator, automatic implantable cardioverter, with cardiac resynchronization (CRT-D) (NIK) · Cardiology
5 more FDA decisions with a free account
Older decisions: P030054-S329, P030054-S292
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Implantable Cardioverter DefibrillatorsNational analysisReview closedCAG-00157R4Updated Nov 19, 2026
- Implantable Cardioverter Defibrillators (ICDs)National determinationOn the books20.4Updated Sep 28, 2026
- Implantable Cardioverter Defibrillators (ICDs)National analysisReview closedCAG-00157NUpdated Sep 15, 2026
- Surveillance of Implantable or Wearable Cardioverter Defibrillators (ICDs): Office, Hospital, Web, or Non-Web BasedLocal determinationIn effectL34087CGS Administrators, LLCUpdated Aug 28, 2026
- Implantable DefibrillatorsNational analysisReview closedCAG-00157R2Updated Nov 19, 2026
- Wireless Stimulation Endocardially for Cardiac Resynchronization Therapy System (WiSE CRT)National analysisReview closedCAG-00471NUpdated Nov 18, 2026
- Implantable Defibrillators - Clinical TrialsNational analysisReview closedCAG-00157RUpdated Sep 15, 2026
- Implantable DefibrillatorsNational analysisReview closedCAG-00157R3Updated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "Promote + RF", any status and sponsor, newest update first.
Quiropraxia y EquilibrioAcademic, hospital or other
NCT05441917 · 48 participants (planned) · Start Sep 1, 2023 · Primary completion Nov 1, 2023
Device: Sanae method with LED; Sanae method with Radiofrecuency · For: Cellulite
Sites: Natal, Brazil
3 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Promote + RF", and for the whole product code for context.
This brand
208 reports: 80 malfunction, 113 injury, 15 death
Whole product code NIK
127,080 reports: 63,286 malfunction, 61,191 injury, 2,565 death
Newest reports for this brand
- PROMOTE RF CRT-DMalfunction
ST. JUDE MEDICAL, INC.(CRM-SYLMAR)
2017865-2022-17413 · Received Aug 11, 2022 · Event dated Aug 8, 2022
Device type: Defibrillator, Automatic Implantable Cardioverter, With Cardiac Resynchronization (Crt-D) (NIK)
Device problem as coded: Stretched
Patient problem as coded: No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
Z-2322-2018 · Started Apr 16, 2018
Reason given: The firm is releasing new firmware for high voltage implantable cardiac devices (ICD) and cardiac resynchronization therapy defibrillators (CRT-D) intended to strengthen security by providing an additional layer of protection against unauthorized device access. For older generation devices not capable of accepting the...
Cause as FDA categorized it: Software design · Device type: Implantable Cardioverter Defibrillator (Non-Crt) (LWS)
34 more recall records with a free account
Published research
The most relevant PubMed records for "Promote + RF"[tiab]. The summary above synthesizes these.
No PubMed record mentions this device by name.
Other devices of this type
Also filed under product code NIK.
- Amplia MRI CRT-DMedtronic Cardiac Rhythm Disease Management · PMA 2022
- Contak CDBoston Scientific Corp · PMA 2022
- Frontier/Frontier Ii/Anthem Family of Crt-PsAbbott Medical · PMA 2016
- Microny Family of PacemakersAbbott Medical · PMA 2016
- Sensolog/Dialog/Regency Family of PacemakersSt. Jude Medical, Inc. · PMA 2016
- Contak Cd,easytrakBoston Scientific Corp · PMA 2026
- Quadra Assura/Unify Assura Family of Crt-DsAbbott Medical · PMA 2016
- Concerto/Insync Sentry/Insync Maximo Implantable Cardiovascular Defibrillators with Cardiac ResynchicnizationMedtronic Cardiac Rhythm Disease Management · PMA 2019
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.